clostridium
difficil
vaccin
approach
mitig
effect
cytomegaloviru
immun
senesc
new
improv
vaccin
develop
recent
year
demonstr
consider
opportun
improv
current
vaccin
develop
new
vaccin
prevent
approach
varieti
diseas
older
adult
strategi
select
appropri
immunolog
target
new
vaccin
develop
evalu
vaccin
may
alter
senesc
immun
respons
term
potenti
benefit
risk
preclin
clinic
trial
phase
vaccin
develop
discuss
vaccin
correl
protect
cell
cell
antibodi
cytokin
granzym
b
influenza
herp
zoster
pneumococcu
cytomegaloviru
chapter
focus
vaccin
prevent
diseas
effect
vaccin
senesc
immun
respons
specif
pathogen
observ
communitydwel
older
adult
relev
experi
anim
model
import
distinguish
studi
older
peopl
nurs
home
set
repres
minor
popul
age
year
older
multipl
chronic
diseas
disabl
frailti
contribut
loss
immun
function
may
longer
repres
senesc
phenotyp
popul
major
older
adult
experi
usual
age
independ
maintain
commun
risk
function
declin
acut
ill
increas
chronic
diseas
burden
frailti
public
health
perspect
usual
age
older
adult
largest
segment
popul
age
year
older
target
popul
new
vaccin
develop
goal
compress
morbid
extrem
life
ad
life
year
second
focu
chapter
highlight
challeng
vaccin
develop
older
adult
vaccin
may
interact
senesc
immun
respons
way
predict
use
standard
correl
protect
antibodi
titer
evalu
potenti
efficaci
goal
vaccin
popul
clinic
protect
seriou
ill
rather
steril
immun
steril
immun
predict
level
antibodi
titer
need
prevent
infect
surrog
vaccin
efficaci
wherea
estim
vaccin
effect
clinic
protect
requir
evalu
humor
cellmedi
immun
respons
vaccin
relev
pathogen
addit
new
vaccin
test
usual
age
older
adult
experi
common
medic
condit
mental
psychosoci
health
issu
may
interact
vaccin
respons
studi
healthi
older
adult
underli
chronic
diseas
disabl
help
us
understand
effect
age
immun
respons
translat
research
improv
health
outcom
older
popul
requir
identif
modifi
risk
agerel
ageassoci
chang
immun
function
influenza
foremost
among
infecti
diseas
term
risk
seriou
complic
death
older
adult
costsav
intervent
popul
least
death
hospit
respiratori
cardiovascular
complic
influenza
occur
annual
unit
state
thompson
et
al
thompson
et
al
spite
efficaci
older
adult
govaert
et
al
current
influenza
vaccin
program
costeffect
older
peopl
even
cost
save
develop
countri
due
reduct
influenzarel
hospit
nichol
et
al
vu
et
al
hospit
rate
dramat
increas
adult
age
year
older
year
influenza
predomin
circul
strain
rel
rate
observ
viru
predomin
circul
strain
fact
season
influenza
vaccin
also
prevent
complic
influenza
pneumonia
heart
attack
stroke
exacerb
congest
heart
failur
provid
even
greater
incent
increas
use
exist
vaccin
develop
new
vaccin
target
improv
vaccin
efficaci
diazgranado
et
al
howev
immun
mechan
underli
increas
risk
complic
ill
recent
declin
season
vaccin
effect
strain
belongia
et
al
poorli
understood
effect
influenza
vaccin
senesc
immun
respons
best
understood
perspect
adapt
immun
respons
influenza
may
alter
vaccin
influenza
vaccin
studi
vaccin
older
adult
well
understood
term
potenti
immunolog
determin
clinic
protect
popul
thu
respons
viru
context
agerel
chang
adapt
immun
system
discuss
signific
detail
exampl
might
anticip
term
potenti
vaccineprevent
diseas
older
peopl
influenza
viru
stimul
antivir
respons
bonemarrowderiv
lymphocyt
b
cell
monocyt
thymusderiv
lymphocyt
cell
result
humor
cellmedi
immun
respect
howev
effect
stimulu
depend
present
viral
peptid
lymphocyt
two
main
cell
type
within
lymphocyt
popul
helper
cell
cytotox
cell
helper
cell
classic
within
cell
subset
subtyp
accord
cytokin
produc
helper
type
helper
type
follicular
helper
tfh
regulatori
treg
helper
type
cell
respons
influenza
viru
adult
popul
result
restimul
previous
prime
respons
exposur
natur
infect
prior
vaccin
virusactiv
cell
varieti
cytokin
mediat
stimul
b
cell
differenti
produc
antibodi
specif
strain
viru
contain
vaccin
virelizi
et
al
specif
antibodi
bind
surfac
glycoprotein
hemagglutinin
ha
neuraminidas
na
neutral
viral
particl
peptid
sequenc
outer
surfac
ha
na
antibodybind
site
chang
result
high
mutat
rate
influenza
viru
select
pressur
immun
system
nativ
viru
phenomenon
known
antigen
drift
chang
ha
identifi
new
circul
strain
influenza
viru
requir
annual
updat
influenza
vaccin
strain
ensur
antibodymedi
immun
stimul
relev
predict
strain
subtyp
influenza
influenza
b
hemagglutin
inhibit
assay
current
industri
standard
measur
antibodi
respons
influenza
vaccin
proxi
vaccin
efficaci
signific
literatur
report
declin
antibodi
respons
influenza
vaccin
age
goodwin
et
al
howev
recent
studi
suggest
observ
declin
may
relat
age
instead
effect
prior
exposur
influenza
reber
et
al
repeat
annual
vaccin
mosterin
hop
et
al
phenomenon
origin
antigen
sin
recent
identifi
antigen
senior
kucharski
et
al
even
though
b
cell
respons
influenza
vaccin
maintain
older
adult
antibodi
respons
appear
impair
differenti
b
cell
antibodyproduc
plasma
cell
due
declin
activ
activationinduc
cytidin
deaminas
aid
transcript
factor
result
highlight
fact
chang
immun
respons
age
attribut
immun
senesc
alon
complic
one
consid
health
statu
studi
particip
vaccin
statu
set
live
clearli
factor
contribut
increas
frailti
expect
caus
declin
immun
respons
result
suggest
addit
mechan
beyond
antibodi
respons
involv
loss
protect
particularli
strain
age
furthermor
even
though
antibodi
respons
vaccin
might
predict
decreas
repeat
vaccin
older
adult
annual
repeat
vaccin
fact
improv
protect
influenza
popul
keitel
et
al
ahm
et
al
voordouw
et
al
annual
repeat
vaccin
children
adult
associ
loss
protect
mclean
et
al
even
abil
mount
fourfold
increas
antibodi
titer
respons
influenza
vaccin
associ
twofold
reduct
influenza
diseas
benoit
et
al
howev
larg
influenza
vaccin
trial
statist
power
determin
protect
consist
steril
immun
antibodi
neutral
viru
prevent
infect
translat
reduc
risk
hospit
thu
correl
clinic
protect
diseas
cellmedi
process
clear
viru
lung
may
requir
vaccinemedi
protect
may
also
relat
durat
antibodi
respons
influenza
vaccin
previou
review
literatur
found
differ
young
older
adult
rate
decay
antibodi
titer
influenza
season
skowronski
et
al
paradigm
shift
understand
limit
antibodi
titer
sole
measur
influenza
efficaci
effro
correl
protect
influenza
studi
shown
serum
antibodi
titer
distinguish
older
adult
go
develop
influenza
ill
may
fail
predict
vaccin
failur
mcelhaney
et
al
mcelhaney
et
al
shahid
et
al
although
antibodi
import
defens
mechan
humor
cellmedi
immun
import
clinic
protect
older
adult
greater
understand
cellmedi
immun
contribut
increas
protect
influenza
need
develop
new
influenza
vaccin
review
mcelhaney
et
al
thu
evalu
antibodi
respons
clinic
trial
new
vaccin
mean
progress
clinic
trial
phase
approv
new
vaccin
may
fail
predict
enhanc
vaccin
efficaci
particularli
efficaci
measur
singl
endpoint
protect
three
vaccin
strain
mcelhaney
et
al
case
vaccin
trial
like
give
true
pictur
enhanc
efficaci
predomin
circul
strain
diazgranado
et
al
contrast
b
cell
mount
subtyp
strainspecif
respons
antigen
determin
cell
respons
conserv
across
differ
strain
influenza
thu
cell
recognit
respons
influenza
degrad
antigen
drift
effro
et
al
butchko
et
al
russel
liew
intern
peptid
sequenc
hemagglutinin
neuraminidas
similar
within
subtyp
influenza
eg
vs
intern
viral
protein
matrix
nucleoprotein
conserv
within
type
influenza
eg
influenza
vs
b
mitchel
callard
thu
peptid
deriv
surfac
glycoprotein
intern
viral
protein
stimul
helper
cell
ctl
respons
crossreact
within
strain
influenza
influenza
b
word
antibodi
respons
rel
strainspecif
cell
respons
crossreact
across
strain
within
influenza
b
immunolog
target
develop
univers
influenza
vaccin
previou
studi
shown
exposur
entir
respiratori
tract
live
influenza
viru
effect
method
induc
crossreact
cell
respons
influenza
viru
infect
nguyen
et
al
direct
comparison
differ
rout
infect
show
protect
correl
size
virusspecif
ctl
respons
lung
associ
lymphoid
organ
although
selfrenew
popul
virusspecif
cell
maintain
lymphoid
organ
mani
year
influenza
respiratori
viru
infect
protect
cellular
immun
shortliv
disappear
within
month
nguyen
et
al
howev
cell
memori
respons
intern
protein
influenza
viru
matrix
nucleoprotein
np
recal
infect
absenc
protect
antibodi
titer
cell
respect
correl
protect
wilkinson
et
al
sridhar
et
al
young
adult
older
adult
ctl
respons
splitviru
influenza
vaccin
older
adult
enhanc
vaccin
expos
influenza
natur
infect
previou
influenza
season
mcelhaney
et
al
viru
taken
process
antigenpres
cell
macrophag
dendrit
cell
result
peptid
present
major
histocompat
complex
activ
cell
helper
cell
h
recogn
antigen
present
major
histocompat
complex
class
ii
mhc
ii
mhc
ii
express
almost
exclus
antigenpres
cell
b
cell
cell
hackett
eisenlohr
contrast
ctl
recogn
viral
peptid
combin
mhc
mhc
express
cell
bodi
enni
et
al
structur
viral
protein
live
inactiv
virus
phagocytoz
macrophag
dendrit
cell
viru
process
within
antigenpres
cell
present
combin
mhc
ii
helper
cell
demotz
et
al
contrast
viral
peptid
present
combin
mhc
gener
product
viral
replic
within
antigenpres
cell
although
antigen
crosspresent
dendrit
cell
recogn
import
contribut
respons
influenza
vaccin
discuss
thu
form
viral
antigen
interact
specif
mhc
cellular
locat
independ
determin
h
ctl
respons
vaccin
hackett
et
al
lamb
et
al
antigen
crosspresent
process
antigen
includ
kill
viru
viral
protein
taken
dendrit
cell
undergo
proteasom
degrad
process
present
mhc
inact
viru
contain
current
parenter
influenza
vaccin
effect
present
mhc
ii
mhc
helper
cell
b
cell
stimul
produc
good
antibodi
respons
weak
ctl
respons
seen
adult
ctl
respons
observ
individu
result
restimul
previous
prime
respons
influenza
natur
infect
hackett
et
al
lamb
et
al
hosaka
et
al
presum
mechan
inactiv
virus
includ
splitviru
influenza
vaccin
stimul
ctl
askona
et
al
relev
antigen
crosspresent
new
vaccin
develop
tolllik
receptor
tlr
ligand
plowden
et
al
behzad
et
al
virosom
huckried
et
al
viruslik
particl
bright
et
al
potenti
adjuv
mcelhaney
et
al
puigbarbera
et
al
use
activ
antigenpres
cell
enhanc
express
mhc
ivir
peptid
complex
improv
poor
ctl
respons
elicit
current
kill
viru
vaccin
boost
cell
respons
import
prioriti
vaccin
develop
gener
due
broader
protect
serolog
distinct
strain
viru
ray
et
al
immunosenesc
alter
sever
aspect
cellmedi
immun
function
vaccin
design
includ
independ
strategi
effect
stimul
helper
cell
ctl
respons
helper
cell
h
mediat
immun
respons
influenza
viru
play
key
role
gener
humor
ctl
respons
influenza
vaccin
h
h
tregulatori
treg
follicular
tfh
h
contribut
immun
respons
interact
b
cell
lymph
node
bone
marrow
h
subset
defin
cytokin
product
andor
locat
within
lymphoid
tissu
h
cytokin
provid
help
along
develop
b
cell
ctl
respons
influenza
downregul
product
treg
h
also
provid
help
b
cell
ctl
ratio
declin
age
skowronski
et
al
invers
correl
risk
influenza
ill
older
adult
mcelhaney
et
al
suggest
shift
toward
respons
influenza
vaccin
import
protect
older
adult
role
inflammatori
cytokin
respons
influenza
inflammag
overproduct
inflammatori
cytokin
older
peopl
associ
increas
risk
agerel
frailti
morbid
disabl
antiinflammatori
respons
involv
mediat
could
potenti
weaken
resist
infect
contribut
healthi
age
franceschi
et
al
contrast
known
inflammatori
respons
viral
infect
trigger
varieti
pathway
involv
host
defens
shown
age
mice
human
addit
inflammatori
cytokin
combin
revers
agerel
defect
h
cytokin
product
prolifer
function
hayn
et
al
recent
studi
shown
combin
effect
restor
influenzaspecif
ctl
function
older
adult
observ
young
adult
mice
human
suggest
mechan
target
develop
protect
vaccin
human
studi
shown
ctl
activ
import
recoveri
influenza
infect
even
absenc
protect
antibodi
infect
viru
strain
mcmichael
et
al
ctl
combat
influenza
viral
infect
recogn
destroy
virusinfect
host
cell
becom
factori
viral
replic
infect
cell
express
surfac
mhc
ivir
peptid
complex
recogn
activ
virusspecif
ctl
enni
et
al
ctl
activ
lead
lysi
virusinfect
cell
perforinor
granulemedi
kill
pasternack
eisen
bleackley
et
al
jenn
tschopp
particularli
import
control
respiratori
viral
infect
doherti
et
al
although
selfrenew
popul
virusspecif
cell
maintain
mani
year
influenza
infect
protect
cellular
immun
shortliv
disappear
within
month
nguyen
et
al
ray
et
al
mcmichael
et
al
even
though
current
inactiv
influenza
vaccin
stimul
ctl
respons
older
even
chronic
ill
older
adult
gors
belsh
respons
degre
crossreact
diminish
compar
young
adult
power
mbawuik
et
al
mcelhaney
robust
respons
vaccin
follow
natur
infect
mcelhaney
et
al
shahid
et
al
virusspecif
kill
mediat
granzym
contain
granul
within
ctl
granul
migrat
immun
synaps
activ
ctl
virusinfect
target
cell
transport
across
cell
membran
cytoplasm
target
cell
involv
enzymat
cascad
lead
apoptot
cell
death
darmon
et
al
granzym
b
grb
key
element
cell
respons
influenza
lung
johnson
et
al
lawrenc
et
al
jenkin
et
al
assay
grb
activ
lysat
influenza
virusstimul
pbmc
correl
cytolyt
activ
ewen
et
al
low
ex
vivo
level
grb
predict
increas
risk
influenza
ill
older
adult
mcelhaney
et
al
mcelhaney
et
al
shahid
et
al
ex
vivo
studi
shown
differ
influenzaspecif
ctl
frequenc
older
compar
young
adult
boon
et
al
suscept
older
adult
may
due
decreas
cytolyt
activ
amount
grb
produc
per
cell
basi
ouyang
et
al
interact
antibodi
cellmedi
immun
respons
influenza
vaccin
inactiv
influenza
viru
vaccin
effect
stimul
helper
cell
older
adult
dysregul
cytokin
product
lead
declin
ratio
respons
live
viru
challeng
defect
b
cell
respons
vaccin
review
frasca
blomberg
contribut
increas
suscept
infect
age
group
weaken
ctl
respons
influenza
poorli
stimul
inactiv
vaccin
contribut
observ
increas
risk
seriou
complic
recent
develop
includ
highdos
influenza
vaccin
contain
four
time
amount
antigen
standard
dose
vaccin
demonstr
improv
efficaci
influenza
ill
enhanc
protect
hospit
pneumonia
influenza
season
liveattenu
intranas
vaccin
develop
provid
effect
stimul
ctl
howev
vaccin
shown
minim
addit
benefit
older
adult
probabl
due
neutral
vaccin
viru
antibodi
nasal
mucosa
gors
et
al
current
effort
focus
use
adjuv
improv
vaccinemedi
protect
age
multipl
immun
respons
stimul
throughout
one
lifetim
gradual
shift
predominantli
cell
increas
proport
memori
cell
thymic
involut
loss
cell
age
may
thu
exhaust
capac
respond
new
antigen
agerel
declin
level
support
thymic
rejuven
correspond
failur
maintain
expand
effector
memori
helper
cell
respons
influenza
kang
et
al
recent
agerel
chang
respons
influenza
associ
persist
cytomegaloviru
cmv
infect
accumul
latedifferenti
cell
revers
normal
cell
ratio
declin
less
one
cmv
seroposit
compar
seroneg
older
adult
declin
cell
respons
influenza
peptid
deriv
influenza
intern
protein
matrix
nucleoprotein
np
seen
young
adult
derhovanessian
et
al
effect
cmv
appear
major
driver
shift
cell
pool
central
effector
memori
subset
review
pawelec
et
al
effect
pronounc
cell
yet
differ
respons
mand
npderiv
peptid
seroposit
versu
seroneg
older
adult
derhovanessian
et
al
result
suggest
addit
mechan
underli
agerel
chang
cell
poor
surviv
predict
invers
cell
ratio
franceschi
et
al
ferguson
et
al
yet
cell
seroposit
seroneg
older
show
enhanc
inflammatori
respons
polyclon
stimul
wikbi
et
al
phenomenon
replic
senesc
associ
chang
relat
finit
number
doubl
cycl
cell
cycl
arrest
occur
effro
ctl
growth
arrest
associ
replic
senesc
also
show
increas
product
sever
proinflammatori
cytokin
resist
apoptosi
loss
costimulatori
molecul
requir
optim
stimul
ctl
effro
et
al
engwerda
et
al
ctl
express
littl
cytolyt
activ
effro
increas
proport
associ
declin
antibodi
respons
influenza
vaccin
goronzi
et
al
saurweinteissl
et
al
reduct
influenzaspecif
memori
ctl
xie
mcelhaney
chang
associ
chronic
cmv
infect
drive
cell
respons
termin
differenti
express
senesc
phenotyp
vasto
et
al
vescovini
et
al
howev
remain
uncertain
extent
chang
may
affect
h
ctl
respons
influenza
influenza
vaccin
influenza
seriou
ill
older
adult
larg
account
rise
hospit
death
rate
acut
cardiac
respiratori
ill
older
peopl
despit
widespread
influenza
vaccin
program
current
vaccin
costsav
new
efficaci
vaccin
recent
approv
margin
improv
still
remain
recent
studi
suggest
signific
opportun
exploit
reserv
capac
cell
respond
influenza
antigen
enhanc
antigen
present
regul
cytokin
respons
addit
adjuv
target
identifi
immunolog
mediat
modul
influenza
risk
older
peopl
screen
candid
vaccin
clinic
trial
use
appropri
correl
protect
popul
critic
develop
effect
influenza
vaccin
age
popul
sinc
earli
phase
vaccin
develop
often
reli
antibodi
titer
surrog
protect
measur
may
fail
detect
robust
cell
respons
thu
effect
vaccin
older
popul
herp
zoster
shingl
pain
blister
rash
result
reactiv
latent
varicellazost
viru
vzv
agent
caus
chickenpox
prior
routin
vaccin
vzv
approxim
peopl
usa
infect
viru
chanc
develop
shingl
one
lifetim
oxman
levin
risk
develop
shingl
dramat
increas
age
older
person
bear
greatest
burden
ill
relat
zoster
also
call
shingl
clinic
condit
result
reactiv
latent
varicellazost
viru
vzv
within
dorsal
root
ganglia
year
million
american
develop
shingl
risk
dramat
increas
age
person
age
suffer
disabl
complic
zoster
postherpet
neuralgia
phn
despit
extens
epidemiolog
studi
risk
immunolog
determin
reactiv
exclus
human
herpesviru
poorli
understood
limit
anim
model
mechanist
studi
cellmedi
immun
essenti
recoveri
herp
zoster
due
signific
cell
tropism
viru
varicella
infect
silent
reactiv
zoster
appear
restimul
vzvspecif
cellular
immun
adulthood
age
boost
immun
system
becom
less
effect
thu
dramat
increas
rate
zoster
phn
age
shingl
import
disabl
diseas
older
adult
vzv
present
chickenpox
childhood
becom
latent
infect
dorsal
root
ganglion
spinal
cord
increas
risk
shingl
age
well
document
annual
incid
age
year
older
astonish
preval
age
year
hopesimpson
schmader
brisson
et
al
reactiv
caus
pain
dermatom
rash
call
shingl
often
follow
phn
chronic
pain
syndrom
defin
pain
last
day
follow
zoster
associ
signific
disabl
older
peopl
incid
phn
almost
neglig
age
least
patient
older
year
almost
beyond
age
becom
affect
follow
attack
shingl
healthrel
qualiti
life
significantli
impact
zoster
year
old
report
pain
median
durat
month
drolet
et
al
function
consequ
pain
significantli
diminish
resolut
zoster
context
phn
pain
impact
daili
function
often
continu
month
drolet
et
al
contrast
shingl
children
rash
gener
follow
mild
case
chicken
pox
littl
clinic
signific
feder
hoss
antivir
therapi
avail
older
peopl
often
present
within
h
window
onset
rash
necessari
initi
effect
treatment
addit
older
peopl
receiv
therapi
within
therapeut
window
still
experi
pain
month
onset
rash
cunningham
dworkin
particularli
given
number
peopl
seek
receiv
time
effect
treatment
shingl
preval
disabl
poor
qualiti
life
relat
phn
major
public
health
concern
signific
literatur
impact
shingl
qualiti
life
older
peopl
variou
therapeut
strategi
manag
phn
review
beyond
scope
chapter
focus
prevent
vaccin
howev
import
perceiv
qualiti
life
psycholog
condit
identifi
epidemiolog
studi
risk
factor
develop
shingl
relev
due
potenti
impact
immun
function
review
studi
suggest
addit
age
poor
selfperceiv
health
psycholog
stress
andor
lack
social
support
mechan
trauma
may
lead
loss
cellmedi
immun
vzvand
increas
risk
shingl
thoma
hall
vzv
exclus
human
herp
viru
cohr
et
al
limit
anim
model
studi
immunolog
mechan
vzv
infect
reactiv
baiker
et
al
howev
much
known
virolog
vzv
infect
studi
liveattenu
oka
vaccin
strain
vzv
show
rapid
evolut
viru
within
first
day
infect
replic
viru
latenc
establish
weinert
et
al
limit
studi
date
appear
resolut
chickenpox
vzvspecif
ctl
access
dorsal
root
ganglion
vzv
live
keep
viral
replic
check
baiker
et
al
arvin
et
al
point
reactiv
latent
vzv
associ
mark
inflamm
dorsal
root
ganglion
lead
nerv
cell
damag
pain
associ
phn
often
preced
onset
dermatom
rash
latent
viru
escap
replic
nerv
skin
caus
pain
condit
continu
even
rash
resolv
appear
relat
central
peripher
nerv
damag
although
gener
declin
circul
vzvspecif
cell
age
cell
demonstr
robust
respons
site
shingl
rash
similar
number
function
seen
young
adult
howev
regulatori
cell
cell
also
accumul
site
infect
older
adult
may
inhibit
activ
otherwis
function
compet
vzvspecif
cell
vukmanovicstej
et
al
vukmanovicstej
et
al
although
identifi
immunolog
correl
protect
zoster
reactiv
vzvspecif
cell
believ
play
central
role
latenc
reactiv
viru
within
dorsal
root
ganglion
arvin
steain
et
al
gowrishankar
et
al
result
highlight
import
design
vaccin
stimul
cellmedi
immun
prevent
reactiv
vzv
protect
zoster
phn
rather
usual
focu
antibodi
respons
prevent
infect
larg
random
doubleblind
placebocontrol
shingl
vaccin
enrol
subject
show
vaccin
compar
placebo
group
reduct
burden
ill
reduct
shingl
case
reduct
shingl
case
complic
postherpet
neuralgia
oxman
et
al
furthermor
reduct
overal
burden
ill
vaccin
subject
show
statist
signific
primari
endpoint
trial
vaccin
strain
vzv
previous
attenu
live
viru
oka
strain
predict
stimul
humor
h
ctl
respons
importantli
diseas
antibodi
titer
predict
protect
reactiv
viru
caus
shingl
postul
mechan
protect
stimul
vzvspecif
cell
respons
vaccin
measur
enzymelink
spot
elispot
assay
smith
et
al
recent
studi
confirm
live
attenu
zoster
vaccin
boost
vzvspecif
cell
sei
et
al
appear
import
prevent
zoster
reactiv
peripher
control
infect
nerv
skin
also
import
highlight
live
attenu
vaccin
oka
zoster
strain
identifi
vzv
isol
skin
shingl
case
vaccin
trial
thu
safe
effect
use
stimul
senesc
immun
respons
recent
recombin
subunit
vaccin
hzsu
contain
vzv
glycoprotein
e
adjuv
system
contain
monophosphoryl
lipid
mpl
develop
includ
twodos
regimen
administ
month
apart
random
placebocontrol
trial
enrol
adult
year
old
demonstr
estim
overal
vaccin
efficaci
herp
zoster
approxim
year
followup
signific
agerel
declin
vaccin
efficaci
although
reaction
vaccin
affect
perform
daili
live
activ
grade
significantli
higher
vaccin
recipi
compar
placebo
recipi
differ
number
particip
went
receiv
second
dose
vaccin
placebo
studi
signific
differ
two
group
seriou
advers
event
potenti
immunemedi
diseas
death
trial
live
viru
vaccin
concern
vzv
infect
immunocompromis
individu
parallel
trial
adult
year
old
use
studi
protocol
design
address
vaccin
efficaci
prevent
postherpet
neuralgia
cunningham
et
al
mechan
protect
relat
hzsu
vaccin
appear
mediat
stimul
cell
specif
glycoprotein
e
subunit
vzv
glycoprotein
e
promot
celltocel
interact
viral
protein
promot
cell
fusion
pathogenesi
viru
enhanc
adapt
immun
respons
glycoprotein
e
depend
activ
dendrit
cell
increas
antigen
present
cell
didierlaur
et
al
howev
zoster
case
studi
evalu
cell
respons
correl
protect
studi
need
determin
immun
respons
glycoprotein
e
offer
protect
herp
zoster
agerel
declin
vaccin
efficaci
shingl
major
debilit
diseas
older
adult
popul
agerel
ageassoci
chang
cellmedi
immun
respons
vzv
clearli
associ
increas
risk
reactiv
viru
caus
shingl
persist
postherpet
neuralgia
fact
antivir
therapi
limit
effect
treatment
zoster
older
adult
point
need
strategi
prevent
diseas
disabl
complic
howev
develop
vaccin
herp
zoster
depend
larg
clinic
trial
determin
vaccin
efficaci
base
clinic
outcom
absenc
reliabl
immunolog
marker
vaccin
efficaci
signific
risk
vaccin
would
fail
show
improv
vaccin
fail
trial
may
limit
interest
industri
move
forward
altern
plan
develop
improv
vaccin
point
need
reliabl
surrog
vaccin
efficaci
test
new
vaccin
earli
phase
clinic
develop
select
vaccin
like
improv
outcom
older
popul
rsv
commonli
circul
viru
winter
month
account
pneumonia
communitydwel
older
adult
review
falsey
import
respiratori
ill
particularli
older
adult
increasingli
recogn
recent
report
rsv
caus
excess
death
second
strain
influenza
caus
death
due
viral
respiratori
ill
age
older
popul
thompson
et
al
mullooli
et
al
although
viru
genet
stabl
time
contrast
influenza
repeat
infect
throughout
adult
life
common
suggest
immun
viru
wane
time
older
adult
increas
risk
sever
diseas
congest
heart
failur
chronic
lung
diseas
sever
immunocompromis
live
longterm
care
facil
falsey
et
al
estim
rsv
diseas
set
rang
resid
per
year
pneumonia
death
case
respect
influenza
ill
older
adult
rsv
result
prolong
length
hospit
stay
signific
disabl
loss
independ
basic
activ
daili
live
need
higher
level
care
hospit
discharg
falsey
et
al
recent
analysi
rsv
ill
context
larg
influenza
vaccin
trial
show
rsv
caus
signific
proport
moder
sever
influenzalik
ill
winter
month
falsey
et
al
studi
immun
respons
rsv
shown
high
level
serum
andor
nasal
antibodi
correl
rel
resist
experiment
challeng
similarli
low
serum
nasal
antibodi
level
risk
factor
infect
diseas
sever
older
adult
agespecif
chang
importantli
older
adult
greater
rise
antibodi
titer
post
infect
younger
counterpart
sinc
rsv
viru
undergo
antigen
drift
time
one
would
predict
result
better
protect
recurr
rsv
ill
would
predict
older
adult
inconsist
rel
increas
risk
rsv
infect
age
shift
respons
rsv
caus
signific
patholog
human
age
mous
model
diminish
ctl
respons
associ
decreas
increas
higher
rsv
titer
lung
zhang
et
al
howev
recent
studi
human
pbmc
show
agerel
chang
cytokin
level
produc
respons
rsv
although
regulatori
balanc
inflammatori
antiinflammatori
cytokin
level
may
alter
looney
et
al
rsv
circul
much
winter
often
cocircul
influenza
midwint
month
present
diagnost
challeng
clinician
symptom
rsv
ill
complet
overlap
relat
influenza
ill
wald
et
al
thu
treatment
approach
would
particularli
problemat
strategi
limit
complic
rsv
none
current
avail
use
adult
develop
vaccin
rsv
proven
signific
challeng
perhap
due
reliabl
antibodi
titer
correl
protect
trial
recent
effort
develop
rsv
vaccin
older
adult
focus
combin
rsv
subunit
protein
adjuv
earli
stage
develop
ongo
challeng
develop
rsv
vaccin
older
adult
correl
protect
poorli
understood
overlap
symptomatolog
cocircul
influenza
winter
month
summari
older
adult
experi
signific
complic
rsv
ill
complic
difficult
distinguish
impact
influenza
base
attack
rate
impact
hospit
older
adult
rsv
like
caus
signific
disabl
older
adult
immunolog
correl
clinic
protect
avail
present
signific
challeng
develop
much
need
vaccin
rsv
older
adult
threat
pandem
influenza
increas
direct
transmiss
highli
pathogen
avian
virus
human
mani
countri
process
complet
plan
manag
anticip
influenza
pandem
anim
transmit
influenza
peopl
close
contact
livestock
addit
mutat
reassort
event
requir
widespread
humantohuman
transmiss
current
research
focus
predict
strain
like
evolv
new
influenza
vaccin
develop
protect
new
strain
develop
effect
pandem
influenza
vaccin
like
continu
relianc
kill
viru
subunit
vaccin
technolog
leav
older
adult
significantli
higher
risk
ill
disabl
death
event
influenza
pandem
target
improv
cell
respons
thu
protect
number
strain
particularli
help
stimul
senesc
immun
system
season
pandem
strain
case
vaccin
stimul
antibodi
respons
new
vaccin
strain
also
prime
cell
respons
influenza
peptid
deriv
agerel
chang
cell
would
result
decreas
product
henc
prolif
respons
vaccin
b
cell
implic
prepandem
pandem
vaccin
prepandem
vaccin
formul
potent
stimul
cell
could
offer
crossprotect
immun
would
enhanc
strainspecif
antibodi
pandem
strain
although
strategi
may
offer
enhanc
protect
older
adult
prepandem
pandem
vaccin
need
test
abil
stimul
adequ
antibodi
respons
also
crossprotect
cellmedi
immun
absenc
improv
current
splitviru
vaccin
technolog
influenza
pandem
could
signific
impact
older
peopl
overwhelm
consequ
health
care
system
individu
age
infecti
diseas
caus
increas
morbid
mortal
especi
evid
older
adult
contract
newli
emerg
diseas
sever
acut
respiratori
syndrom
sar
kill
infect
individu
age
chen
et
al
rapid
humantohuman
transmiss
sar
expos
entir
age
spectrum
novel
viru
highlight
chang
immun
system
lead
increas
morbid
mortal
rate
age
fortun
outbreak
control
without
vaccin
could
reach
epidem
proport
older
adult
may
also
virus
west
nile
viru
wnv
human
immunodefici
viru
hiv
appear
increas
risk
seriou
complic
virus
contract
age
host
senesc
immun
system
may
produc
less
effect
respons
compar
young
adult
evid
declin
epidemiolog
studi
show
much
higher
mortal
rate
older
compar
young
adult
wnv
nash
et
al
howev
recent
studi
shown
loss
age
polyfunction
cell
respond
wnv
infect
lelic
et
al
remain
determin
whether
chang
cell
may
role
suppress
cell
respons
hiv
preval
increas
age
popul
hivinfect
patient
age
year
older
hivinfect
popul
unit
state
casau
hiv
age
associ
develop
replic
senesc
lymphocyt
increas
risk
infect
effro
replic
senesc
result
chronic
stimul
immun
system
associ
telomer
shorten
loss
express
cell
van
baarl
et
al
chang
need
consid
develop
new
therapi
improv
immun
system
respons
vaccin
effro
recent
popul
memori
cell
phenotyp
identifi
potenti
target
immunotherapi
treatment
persist
infect
hiv
pulko
et
al
streptococcu
pneumonia
import
caus
morbid
mortal
lead
caus
commun
acquir
infect
includ
bacteri
pneumonia
mening
bacteremia
amongst
highest
risk
group
bear
greatest
burden
diseas
develop
world
adult
age
year
older
although
current
vaccin
contain
pneumococc
capsular
polysaccharid
costeffect
popul
fedson
sisk
et
al
efficaci
may
limit
ageassoci
chang
immun
respons
vaccin
although
agerel
declin
antibodi
respons
pneumococc
vaccin
healthi
young
older
adult
compar
consist
antibodi
respons
serotyp
contain
vaccin
may
achiev
older
adult
rubin
et
al
addit
opsonophagocyt
activ
major
effector
mechan
clear
pneumococcu
appear
declin
age
kolibab
et
al
signific
declin
antibodi
titer
pp
year
follow
pneumococc
vaccin
musher
et
al
recommend
vaccin
age
current
review
includ
new
proteinconjug
vaccin
contain
nontox
diphtheria
toxin
conjug
serotyp
pneumococc
polysaccharid
larg
random
placebocontrol
trial
pcv
conduct
netherland
almost
adult
year
age
demonstr
estim
vaccin
efficaci
invas
bacteremia
noninvas
pneumonia
pneumococc
diseas
year
follow
vaccin
bonten
et
al
trial
util
novel
antigen
detect
assay
pneumococc
serotyp
urin
diagnosi
pneumococc
bacteremia
pneumonia
prior
develop
assay
vaccin
efficaci
effect
studi
limit
diagnosi
pneumococc
diseas
detect
pneumococcu
sputum
blood
cerebrospin
fluid
pose
signific
challeng
studi
older
adult
studi
shown
introduct
childhood
vaccin
schedul
led
herd
immun
older
adult
wherebi
circul
serotyp
contain
vaccin
begin
declin
thu
transmit
older
adult
previou
studi
base
detect
invas
pneumococc
diseas
recent
studi
util
urinari
antigen
detect
shown
protect
appli
invas
noninvas
pneumococc
diseas
older
adult
van
werkhoven
et
al
observ
support
emerg
polici
pneumococc
vaccin
older
adult
includ
vaccin
schedul
vaccin
contain
purifi
pneumococc
polysaccharid
stimul
antibodi
product
tindepend
type
respons
one
requir
cell
help
lack
memori
bruyn
finnish
studi
older
adult
show
serotyperel
differ
serum
antibodi
respons
suggest
serotyp
weak
immunogen
older
adult
sankilampi
et
al
tindepend
respons
shortliv
may
adequ
boost
revaccin
proteinconjug
pneumococc
vaccin
pcv
develop
facilit
cell
cooper
perri
catteral
thu
may
effect
target
cell
respons
known
declin
age
although
fewer
serotyp
repres
current
vaccin
appear
effect
albeit
serotyp
contain
vaccin
known
crossreact
antibodi
respons
differ
serotyp
polysaccharid
light
enhanc
efficaci
anticip
increas
circul
serotyp
due
effect
herd
immun
pneumococc
vaccin
schedul
older
adult
modifi
includ
follow
provid
protect
serotyp
contain
cytokin
respons
pneumococc
antigen
shown
regul
respons
proteinand
polysaccharidespecif
antibodi
respons
khan
et
al
may
import
pathogenesi
pneumococc
diseas
kemp
et
al
cytokin
respons
whole
pneumococcu
could
explain
chang
virul
differ
serotyp
older
adult
robinson
et
al
comparison
cytokin
respons
younger
adult
arva
andersson
produc
macrophag
associ
initi
inflammatori
respons
pneumococc
invas
perri
catteral
van
der
poll
et
al
found
import
develop
antibodi
pneumococc
surfac
protein
khan
et
al
khan
et
al
increas
level
antiinflammatori
cytokin
product
macrophag
regulatori
cell
associ
increas
risk
pneumococc
infect
van
der
poll
et
al
cytokin
becom
import
immunomodul
inflammatori
respons
recoveri
pneumococc
infect
william
et
al
moreov
gut
microbiota
shown
mous
model
role
regul
defens
mechan
pneumococc
pneumonia
schuijt
et
al
suggest
dysregul
cytokin
respons
age
may
complic
ascrib
immun
senesc
alon
vaccin
alzheim
diseas
alzheim
diseas
ad
caus
deposit
protein
brain
toxic
effect
lead
neuron
cell
death
amyloid
plaqu
format
develop
neurofibrillari
tangl
base
upon
studi
mice
vaccin
contain
peptid
shown
stimul
antibodi
product
improv
cognit
function
mous
model
ad
vaccin
advanc
phase
ii
clinic
trial
base
demonstr
signific
advers
effect
vaccin
phase
trial
includ
subject
phase
ii
trial
halt
due
develop
asept
meningoencephil
vaccin
subject
analysi
antibodi
respons
show
trend
toward
cognit
enhanc
respond
vaccin
antibodi
titer
respond
compar
nonrespond
develop
asept
meningoencephil
patton
et
al
result
suggest
advers
effect
vaccin
relat
immun
respons
vaccin
rather
toxic
postmortem
studi
meningoencephil
case
show
substanti
clear
brain
mark
cell
infiltr
brain
tissu
postul
agerel
defect
lead
patholog
ad
relat
apc
uptak
stimul
cytokin
inflammatori
respons
defect
associ
ineffici
phagocytosi
product
inflammatori
cytokin
chemokin
nitric
oxid
lead
complement
activ
cell
apoptosi
immun
mechan
target
vaccin
celldepend
antibodi
product
form
complex
effici
clear
earlier
studi
shown
effect
stimul
prolif
respons
human
peripher
blood
mononuclear
cell
pbmc
respons
increas
older
compar
young
adult
subject
signific
increas
observ
older
adult
subject
ad
shown
respons
b
cell
stimul
product
antibodi
effect
stimul
cell
prolifer
product
h
h
cytokin
h
vs
h
respons
ad
mous
model
associ
effect
clearanc
mous
model
adjuv
ad
vaccin
use
human
trial
stimul
respons
vaccin
postul
adjuv
vaccin
activ
memori
cell
migrat
site
deposit
brain
produc
cytokin
although
antibodi
respons
appear
effect
clear
inflammatori
cytokin
respons
cell
infiltr
lead
meningoenceph
sinc
stimul
cytokin
appear
addit
adjuv
may
respons
seriou
advers
effect
vaccin
monsonego
weiner
effort
continu
develop
immunologicbas
therapi
ad
result
clinic
trial
continu
signific
consequ
futur
vaccin
develop
recent
review
cite
critic
need
new
develop
strategi
marciani
agerel
chang
immun
system
associ
increas
risk
infecti
diseas
larg
attribut
agerel
chang
cellmedi
immun
defect
defens
mechan
mediat
ctl
would
suggest
potent
vaccin
older
adult
stimul
ctl
particular
pathogen
howev
underli
mechan
defect
immun
respons
older
peopl
remain
poorli
understood
includ
potenti
neg
impact
elev
level
inflammatori
cytokin
includ
suppress
effect
regulatori
cell
complex
set
interact
activ
protect
immun
respons
highlight
import
develop
correl
protect
identifi
novel
target
vaccin
develop
improv
protect
varieti
infecti
diseas
older
adult
spite
limit
understand
number
avail
vaccin
shown
costeffect
even
costsav
older
adult
futur
research
better
understand
immunolog
target
prevent
treatment
varieti
acut
chronic
diseas
prevent
disabl
older
adult
make
signific
contribut
ad
life
year
